Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

Shelley Wood

November 06, 2022

News Daily News

Coronary Revascularization Benefits Even Latecomer STEMI: FAST-MI Registry

Michael O'Riordan

September 21, 2021

News Conference News ESC 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

Todd Neale

August 24, 2021

News Daily News

‘Smart’ Approach Wins for Post-PCI Antiplatelet Prescribing

Yael L. Maxwell

April 19, 2021

News Daily News

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

Michael O'Riordan

November 03, 2020

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Shelley Wood

October 14, 2020

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

Todd Neale

October 14, 2020

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

L.A. McKeown

October 14, 2020

News Daily News

Reduced-Dose Prasugrel Works Well in Older, Low-Weight ACS Patients

Todd Neale

July 21, 2020

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Daily News

活化凝血时间可能预测单纯使用肝素的 PCI 的缺血事件

L.A. McKeown

April 28, 2015

News Daily News

El Tiempo de Coagulación Activado podría Predecir los Episodios Isquémicos en Pacientes PCI a Tratamiento Solo con Heparina

L.A. McKeown

April 28, 2015

News Daily News

Activated Clotting Time May Predict Ischemic Events in PCI Patients on Heparin Alone

L.A. McKeown

April 28, 2015

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

Presentation TCT 2013

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Presenter: Salvatore Cassese, Robert Byrne, Tomohisa Tada, Lamin King, Adnan Kastrati

January 31, 2013

News Daily News

Meta-analysis Questions Benefit of Longer Dual Antiplatelet Therapy Post-PCI

November 28, 2012

News Daily News

Meta-análisis cuestiona beneficio de la terapia antiplaquetaria doble extendida después la PCI

November 28, 2012

Presentation TCT 2012

ISAR-SAFE Update

Presenter: Adnan Kastrati

October 22, 2012

News Daily News

La Bivalirudina Reduce las Hemorragias en Pacientes NSTEMI sometidos a PCI

Jason Kahn

October 19, 2012

News Daily News

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Jason Kahn

October 19, 2012

Advertisement

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

Coronary Revascularization Benefits Even Latecomer STEMI: FAST-MI Registry

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

‘Smart’ Approach Wins for Post-PCI Antiplatelet Prescribing

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

Reduced-Dose Prasugrel Works Well in Older, Low-Weight ACS Patients

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

活化凝血时间可能预测单纯使用肝素的 PCI 的缺血事件

El Tiempo de Coagulación Activado podría Predecir los Episodios Isquémicos en Pacientes PCI a Tratamiento Solo con Heparina

Activated Clotting Time May Predict Ischemic Events in PCI Patients on Heparin Alone

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Meta-analysis Questions Benefit of Longer Dual Antiplatelet Therapy Post-PCI

Meta-análisis cuestiona beneficio de la terapia antiplaquetaria doble extendida después la PCI

ISAR-SAFE Update

La Bivalirudina Reduce las Hemorragias en Pacientes NSTEMI sometidos a PCI

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content